CD274 and neoplasm: In an immunogenomic analysis of TCGA data and clinical trials of anti-PD-(L)1 therapy, 9p21 loss confers “cold” tumor-immune phenotypes [74], characterized by reduced abundance of TILs, particularly, T/B/NK cells, altered spatial TILs patterns, diminished immune cell trafficking/activation, decreased rate of PD-L1 positivity, along with activation of immunosuppressive signaling.